Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Valued as a loss-making company: Sales comps, Analyst consensus, and Net cash floor.
ACCE opinionX4 Pharmaceuticals Inc. Common Stock (XFOR)
Fair value
Not available
ACCE price target
$2.50
Rating
Not rated
Horizon
12 months
ACCE price target published on 15 Oct 2026, 00:00 CEST.
Price used: $3.24 at the close on 23 Oct 2026, 22:00 CEST.
Models: Analyst consensus, Net cash floor, and Sales comps.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
42
out of 100
Analysts
100% buy
5 covering
P/E
162.0x
forward -4.2x
1-year return
+4.9%
Dividend yield
0.00%
X4 Pharmaceuticals Inc. Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
X4 Pharmaceuticals is a clinical-stage biotech developing mavorixafor, an oral CXCR4 antagonist that it has taken into commercial launch for chronic neutropenia and WHIM syndrome. The moat rests on the product's orphan-drug exclusivity and a small, specialist prescriber base, but that is a narrow franchise, and the company is still losing money heavily: operating margin is -186.1% and ROE is -113.1%. Revenue growth of 346.3% reflects a very small starting base rather than a mature business, so the number tells you the launch has begun, not that it is profitable. The near-term catalysts are sales uptake of the commercial product and pipeline readouts in the company's other programs, and both are binary enough that the balance sheet and cash runway will matter as much as the science. At a 262M USD market cap with a 40/100 score and no index membership, the name is small and under-followed, which is worth a closer look mainly to test whether launch trajectory can outrun the cash burn.
⚠ Investor warnings · 3 flagsAI-assisted·How I use AI
high
Heavy cash burn
Free cash flow is -$88.6M against a $299M market cap, and operating margin is -186.1%. The company needs to keep raising or find revenue fast.
moderate
Price above ACCE target
The stock trades 29.6% above the ACCE price target of $2.50, with the current price at $3.24.
moderate
Loss-making earnings
Net margin is +0.0% with ROE at -113.1%, and the P/E of 151.0 rests on very thin earnings. Revenue growth of +346.3% does not yet reach the bottom line.
AI research notes
AI-assisted·How I use AIWritten Oct 20, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
Revenue grew 346.3% year over year, far faster than the 63.6% average annual pace of the past five years.
The latest quarter beat expectations, with earnings per share of -0.13 against -0.19 expected, a 31.6% surprise.
Why it could disappoint
The company burned $89M of free cash over the last twelve months, and its free cash flow yield is -34.5%.
The diluted share count rose 531.0% in the last fiscal year, a heavy dilution that shrinks each shareholder's stake.
Return on equity is -113.1% and the trailing P/E is 151.0x at a $3.24 share price, which leaves little room for error.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Next results
Nov 4, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where XFOR's valuation models land
Price
$3.24
Model fair valueConfidence: low
about $4.94
Model
Fair value
Upside
Analyst consensus
Net cash floor
Sales comps
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores